Experimental HIV Drugs
Experimental HIV Drugs
ICAAC 2012: New Tenofovir Pro-drug Matches Potency of Original Version but with Less Toxicity
- Details
- Category: HIV Treatment
- Published on Tuesday, 06 November 2012 00:00
- Written by Liz Highleyman
Tenofovir alafenamide fumarate (TAF), the tenofovir pro-drug formerly known as GS-7340, has antiviral potency similar to that of tenofovir disoproxil fumarate (TDF), and a new "quad" formulation containing TAF works as well as the Stribild single-tablet regimen (elvitegravir/cobicistat/TDF/emtricitabine) but appears to be easier on the bones and kidneys, according to recently released data.
ICAAC 2012: Novel NNRTI MK-1439 Shows Potent Activity, Distinct Resistance Profile
- Details
- Category: HIV Treatment
- Published on Wednesday, 26 September 2012 00:00
- Written by Liz Highleyman
The novel non-nucleoside reverse transcriptase inhibitor (NNRTI) MK-1439 exhibited good activity against a variety of HIV subtypes and maintained its potency against most common NNRTI-resistant viruses, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this month in San Francisco. 
ICAAC 2012: Dolutegravir HIV Regimen Superior to Atripla, Fewer Stop Due to Side Effects
- Details
- Category: HIV Treatment
- Published on Friday, 14 September 2012 00:00
- Written by Liz Highleyman
The experimental integrase inhibitor dolutegravir combined with abacavir/lamivudine (Epzicom) demonstrated statistically superior antiviral efficacy compared with the popular Atripla single-tablet regimen for first-line HIV treatment, largely because fewer people stopped using the former due to side effects, researchers reported this week at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this week in San Francisco.
DHHS Panel Adds Stribild Quad Pill As Alternative Regimen for Treatment-naive HIV Patients
- Details
- Category: Approved HIV Drugs
- Published on Thursday, 20 September 2012 00:00
- Written by Liz Highleyman
The U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents issued a statement this week indicating that the newly approved Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) single-tablet regimen has been included as an alternative regimen option for people starting HIV treatment for the first time. 
ICAAC 2012: Long-acting Integrase Inhibitor S/GSK1265744 Active Against HIV Subtypes
- Details
- Category: HIV Treatment
- Published on Friday, 14 September 2012 00:00
- Written by Liz Highleyman
The experimental integrase inhibitor S/GSK1265744 exhibited potent and prolonged activity against a broad range of HIV subtypes, was active against clones with resistance to raltegravir (Isentress) and elvitegravir, and appears to have a high barrier to resistance, according to a presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco.
More Articles...
- ICAAC 2012: New Long-acting HIV Fusion Inhibitor Albuvirtide Looks Promising in Early Studies
- Coverage of the 2012 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Coverage of 2012 Interscience Conference on Antimicrobial Agents and Chemotherapy
- HIV Attachment Inhibitor BMS-663068 Looks Good in Early Studies
Web Design and Development by